BioSpace News Archive

On December 28, the U.S. Food and Drug Administration reported there had been 50 novel drug approvals for the year, and that was just for new chemical entities.

The findings may have far-reaching consequences for any COVID-19 vaccines in development that are based upon targeting the well-conserved SARS-CoV-2 nucleocapsid (N-) protein.

Telix Pharmaceuticals Limited, a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on molecularly targeted radiation, announces that the United States Food and Drug Administration has approved Telix’s lead prostate cancer imaging product, Illuccix®.

HUTCHMED Limited announces that it has been included by FTSE Russell in the FTSE Global Equity Index Series in its quarterly review, including the FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes.

CANbridge Pharmaceuticals, Inc. announced that James Xue, Ph.D., Founder, Chairman and CEO, attended the launch ceremony of the Chinese Red Cross Foundation Rare Disease Mutual Assistance Fund, at the China Rare Diseases Conference 2021, in Beijing, on December 18th, as the representative of CANbridge, one of the founding sponsors of the Fund.

Antengene Corporation Limited, a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announced dosing in Australia of the first subject in the Phase I PROBE Trial, a first-in-human study of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin’s lymphoma.

Prestige BioPharma Limited, a Singapore-based biopharmaceutical with operations in USA and South Korea, commences construction of Innovative Discovery Center in Busan, South Korea.